Expertise in
26
conditions

Alessandro Aiuti

Milan, IT 
Expertise in
26
conditions
Milan, IT 
OverviewLocationsClinical Research

Overview

Alessandro Aiuti practices in Milan, Italy. Mr. Aiuti is highly rated in 26 conditions, according to our data. His top areas of expertise are Wiskott-Aldrich Syndrome, Adenosine Deaminase Deficiency, Metachromatic Leukodystrophy, Bone Marrow Transplant, and Splenectomy.

His clinical research consists of co-authoring 215 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Milan, Italy
Other Locations
Monza, Italy
San Raffaele, Italy
Rome, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase I/II Study Evaluating Safety and Efficacy of Autologous Hematopoietic Stem and Progenitor Cells Genetically Modified With IDUA Lentiviral Vector Encoding for the Human α-L-iduronidase Gene for the Treatment of Patients Affected by Mucopolysaccharidosis Type I, Hurler Variant
Phase I/II Study Evaluating Safety and Efficacy of Autologous Hematopoietic Stem and Progenitor Cells Genetically Modified With IDUA Lentiviral Vector Encoding for the Human α-L-iduronidase Gene for the Treatment of Patients Affected by Mucopolysaccharidosis Type I, Hurler Variant
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2025
Intervention Type: Genetic
Study Phase: Phase 1/Phase 2
A Phase I/II Clinical Trial of Hematopoietic Stem Cell Gene Therapy for the Wiskott-Aldrich Syndrome
A Phase I/II Clinical Trial of Hematopoietic Stem Cell Gene Therapy for the Wiskott-Aldrich Syndrome
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Genetic
Study Drug: OTL-103 Autologous CD34-Positive Bone Marrow and/or Peripheral Blood-Derived Cells
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

213 Total Publications

Autoantibodies neutralizing type I IFNs in 40% of patients with WNV encephalitis in seven new cohorts.
Autoantibodies neutralizing type I IFNs in 40% of patients with WNV encephalitis in seven new cohorts.
Journal: medRxiv : the preprint server for health sciences
Published: September 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Aiuti's expertise for a condition
ConditionClose
View All 9 Elite Conditions
View All 9 Distinguished Conditions
View All 8 Advanced Conditions
View All 39 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile